SCHEMBL6133650

SCHEMBL6133650

CN(C)c1ncc(-c2ccc(=O)n(C)n2)c(-c2ccc(Cl)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 14/20 0.51
CYP1A2 P05177 13/20 0.51
CASP1 P29466 13/20 0.51
CASP7 P55210 13/20 0.51
HSD17B10 Q99714 12/20 0.51
HIF1A Q16665 11/20 0.51
USP2 O75604 10/20 0.51
MEN1 O00255 6/20 0.44
KMT2A Q03164 6/20 0.44
CYP2D6 P10635 5/20 0.44
GLA P06280 4/20 0.44
TSHR P16473 2/20 0.44
BRCA1 P38398 1/20 0.44
MAPK1 P28482 3/20 0.44
LMNA P02545 2/20 0.44
HPGD P15428 2/20 0.44
ALOX15 P16050 1/20 0.44
KDM4E B2RXH2 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133837 0.86 ALDH1A1 (0.53) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL6134360 0.83 LMNA (0.47) MEN1KMT2ALMNAKDM4EPOLB
SCHEMBL6133247 0.80 CASP1 (0.43) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL6134316 0.79 HRH3 (0.43) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL6133485 0.74 ALDH1A1 (0.44) ALDH1A1CYP1A2CASP1CASP7HSD17B10
SCHEMBL11144982 0.73 HRH3 (0.54) MEN1KMT2AGLATSHRKDM4E
SCHEMBL6133620 0.72 ADORA1 (0.52) MEN1KMT2ATSHRMAPK1LMNA
SCHEMBL6134537 0.72 RPS6KA3 (0.48) KMT2ALMNAHRH3
SCHEMBL11405317 0.72 HRH3 (0.52) MEN1KMT2AGLATSHRKDM4E
SCHEMBL6134043 0.71 ADORA1 (0.53) KMT2AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 ALDH1A1 801/4885CYP1A2 1170/4885CASP1 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.